Minoryx recibe la aprobación de la Agencia Reguladora Española para iniciar el estudio de fase 2 en la ataxia de Friedreich

by Minoryx Therapeutics

La ataxia de Friedreich es una enfermedad rara neurodegenerativa que se diagnostica antes de los 25 años. En España afecta a unas 2.000 personas. El ensayo FRAMES iniciará el reclutamiento de pacie...

Read more

Minoryx Therapeutics raises €21.3M in Series B funding round

by Ysios Capital

The funding round was led by Fund+, joined by SFPI-FPIM, S.R.I.W. and Sambrinvest, in addition to all Series A investors (Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi V...

Read more

Minoryx inicia el ensayo de fase II/III del tratamiento para la adrenomieloneuropatía

by Minoryx Therapeutics

El primer paciente con esta enfermedad rara que ha iniciado el tratamiento con MIN-102 ha sido en el Hospital Vall d'Hebron de Barcelona. El estudio, denominado ADVANCE, reclutará en total a 100 paci...

Read more

Minoryx successfully completes phase 1 clinical trial for lead candidate MIN-102

by Professional Newco

Minoryx Therapeutics – a drug development company specialized in the discovery and development of new drugs for orphan diseases, which has R& D laboratories at the Barcelona Science Park– announce...

Read more

Minoryx Therapeutics receives Orphan Drug Designation from the US FDA for its lead candidate MIN-102

by Professional Newco

MIN-102 targets X-linked Adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with high unmet medical need. Orphan drug status for MIN-102 has now been granted by both the FDA and the E...

Read more

Minoryx Therapeutics receives European Orphan Drug Designation for its lead candidate MIN-102

by Professional Newco

MIN-102 is a selective PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept in multiple animal models. Phase I studi...

Read more

Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102

by Ysios Capital

MIN-102 is a differentiated PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept. The aim of the Phase 1 study is to...

Read more

Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)

by Ysios Capital

Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners ...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

El Marañón investiga la eficacia de un...

by Hospital General Universitario Gregorio Marañón

El proyecto “Dabalvancina como tratamiento local para las complicaci...

Photos Stream